Additional file 1 of Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
Creators: name: Olbertova, Helena
name: Plevova, Karla
name: Pavlova, Sarka
name: Malcikova, Jitka
name: Kotaskova, Jana
name: Stranska, Kamila
name: Spunarova, Michaela
name: Trbusek, Martin
name: Navrkalova, Veronika
name: Dvorackova, Barbara
name: Tom, Nikola
name: Pal, Karol
name: Jarosova, Marie
name: Brychtova, Yvona
name: Panovska, Anna
name: Doubek, Michael
name: Pospisilova, Sarka
Publisher: name: figshare
Year: 2022
Subjects: subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Cancer
subject: Hematology
subject: 110309 Infectious Diseases
subject: FOS: Health sciences

description: Additional file 1: Supplementary Table 1. Antibodies used for BCR signaling activity assessment. Supplementary Table 2. Results of relative telomere length (RTL) quantification in the basic CLL cohort (n = 198). Supplementary Table 3. TP53 mutation evolution cohort – overview of clinico-biological features and results in baseline and follow-up samples, PART A Abbreviations: ALZ – alemtuzumab; BR - bendamustine and rituximab; CLB – chlorambucil; CR - cyclophosphamide and rituximab; del - deletion; F – female; FCR - fludarabine, cyclophosphamide, and rituximab; FISH - fluorescence in situ hybridization; hyper CVAD - hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; IGHV – immunoglobulin heavy chain variable region; M – male; M – mutated; mo – months; U – unmutated; yrs – years. Supplementary Table 3. TP53 mutation evolution cohort – overview of clinico-biological features and results in baseline and follow-up samples, PART B Abbreviations: LTD – lymphocyte doubling time; mo – months; mut – mutated; p – phosphorylated; RTL – relative telomere length; VAF – variant allele frequency; wt – wildtype. Supplementary Figure 1. RTL of the entire CLL cohort was compared to the telomere length of a control DNA sample pooled from healthy individuals, arbitrarily set to RTL = 1 (green line). Median RTL of CLL cases (black line) was 0.81, range 0.46 – 1.25. Supplementary Figure 2. A) Rai (n = 130) and B) Binet (n = 133) stages at diagnosis in untreated CLL samples and their associations with RTL. The significant associations were P 0 vs III-IV = 0.0018; P I-II vs III-IV = 0.0108; P A vs C = 0.0043. Supplementary Figure 3. Overall survival (OS) of A) the entire CLL cohort (n = 198) divided by RTL above (“RTL long”) and below (“RTL short”) median RTL value (median RTL = 0.84; OS long RTL = 119; OS short RTL = 91; OS P = 0.0004); and B) of CLL patients with mutated TP53 status (n = 40) divided by RTL above (“RTL long”) and below (“RTL short”) median RTL value in this subgroup (median RTL = 0.78; OS long RTL = 86; OS short RTL = 55; OS P = 0.046). Supplementary Figure 4. hTERT expression in A) the baseline samples (P shortening vs. stable = 0.66; P stable vs. prolonging = 0.08; P shortening vs. prolonging = 0.45) and in B) the follow-up samples (P shortening vs. stable = 0.77; P stable vs. prolonging = 0.52; P shortening vs. prolonging = 0.82), (RTL shortening n = 10; stable n = 10; prolonging n = 6). C) Comparison of hTERT values in serial samples. hTERT expression did not associate with RTL prolongation. Supplementary Figure 5. Lymphocyte doubling time did not correlate with a change of RTL time during the disease course (Pearson r = -0.175; P = 0.45). Supplementary Figure 6. p-ZAP70/SYK significantly correlated with p-ERK1/2 in A) baseline samples (Pearson R = 0.82; P = 0.002) and B) follow-up samples (Pearson R = 0.92; P &lt; 0.001).